Common malignant tumors of the musculoskeletal system in children, adolescents, and
young adults (< 30 years old) include rhabdomyosarcoma, osteosarcoma, and Ewing's …

Rhabdomyosarcoma (RMS) is a malignant childhood tumor of mesenchymal origin that
currently has a greater than 70% overall 5-year survival. Multimodality treatment is …

Purpose This prospective phase II study was designed to assess disease control and to
describe acute and late adverse effects of treatment with proton radiotherapy in children with …

Appropriate imaging is essential in the treatment of children and adolescents with
rhabdomyosarcoma. For adequate stratification and optimal individualised local treatment …

Soft tissue sarcomas in children are rare. Approximately 850 to 900 children and
adolescents are diagnosed each year with rhabdomyosarcoma (RMS) or a non-RMS soft …

Abstract Learning Objectives After completing this course, the reader will be able to: Interpret
the histologic findings of rhabdomyosarcoma and differentiate rhabdomyosarcoma from …

Abstract The Children's Oncology Group (COG) uses Clinical Group (CG) and modified
Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on …

This review also provides a complete list of diagnostic tests and imaging required to identify
rhabdomyosarcoma in any body site. Rapid diagnosis and recognition of this rare disorder …

Purpose Regional lymph node disease (RLND) is a component of the risk-based treatment
stratification in rhabdomyosarcoma (RMS). The purpose of this study was to determine the …

Five‐year overall survival (OS) of localized RMS exceeds 70% in children (< 18) but is very
poor in adult patients. We analyzed the outcome and prognostic factors (PF) of a national …